Dekabank Deutsche Girozentrale Reduces $229K in Caribou Biosciences, Inc. ($CRBU)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Dekabank Deutsche Girozentrale reduced its position in Caribou Biosciences, Inc. ($CRBU), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Caribou Biosciences, Inc. after selling 130,000 shares during the quarter.
Caribou Biosciences, Inc. Stock Up 8.6%
Shares of Caribou Biosciences, Inc. ($CRBU) traded around $1.76 on Saturday, up 8.6% for the day.
Caribou Biosciences, Inc. Earnings
Analysts Set New Price Targets
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Get Caribou Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CRBU, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.